Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/12/2025 | Buy → Hold | Needham | |
| 4/28/2025 | $55.00 | Buy → Hold | Stifel |
| 2/6/2025 | $85.00 → $70.00 | Overweight → Neutral | Analyst |
| 2/1/2024 | $119.00 → $129.00 | Buy | Needham |
| 5/22/2023 | $140.00 | Buy | CL King |
| 3/27/2023 | $124.00 | Sector Weight → Overweight | KeyBanc Capital Markets |
| 3/21/2023 | $96.00 | Equal Weight | Wells Fargo |
| 10/12/2022 | $85.00 | Hold | Jefferies |
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
4 - CONMED Corp (0000816956) (Issuer)
3 - CONMED Corp (0000816956) (Issuer)
Needham downgraded CONMED from Buy to Hold
Stifel downgraded CONMED from Buy to Hold and set a new price target of $55.00
Analyst downgraded CONMED from Overweight to Neutral and set a new price target of $70.00 from $85.00 previously
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
SC 13G/A - CONMED Corp (0000816956) (Subject)
8-K - CONMED Corp (0000816956) (Filer)
8-K - CONMED Corp (0000816956) (Filer)
10-Q - CONMED Corp (0000816956) (Filer)
CONMED Corporation (NYSE:CNMD) today announced that Kim Kelderman will be joining its Board of Directors effective September 8, 2025. "My fellow directors and I are delighted to welcome Kim to the board," said LaVerne Council, Chair of CONMED's Board of Directors. "Kim brings extensive global leadership experience across life sciences businesses, with a strong track record in innovation and strategy. Kim's skills and insights will be valuable additions to the board." "Kim is an excellent addition to the board," said Patrick Beyer, President and Chief Executive Officer of CONMED. "We are excited to benefit from his extensive experience and valuable perspective as we pursue our long-term
CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based
CONMED Corporation (NYSE:CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales of $342.3 million increased 3.1% year-over-year as reported and 2.9% in constant currency. Domestic revenue increased 2.8% year-over-year. International revenue increased 3.4% year-over-year as reported and 2.9% in constant currency. Diluted net earnings per share (GAAP) were $0.69, compared to diluted net earnings per share (GAAP) of $0.96 in the second quarter of 2024. Adjusted diluted net earnings per share(1) were $1.15, compared to adjusted diluted net earnings per share of $0.98 in the second quarter of 2024. "We are enco
CONMED Corporation (NYSE:CNMD) today announced that its Board of Directors declared a quarterly cash dividend of $0.20 per share on August 7, 2025, payable on October 3, 2025, to all shareholders of record as of September 15, 2025. About CONMED Corporation CONMED is a medical technology company that provides devices and equipment for surgical procedures. The Company's products are used by surgeons and other healthcare professionals in a variety of specialties, including orthopedics, general surgery, gynecology, thoracic surgery, and gastroenterology. For more information, visit www.conmed.com. Forward-Looking Statements This press release may contain forward-looking statements based
CONMED Corporation (NYSE:CNMD) today announced financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales of $342.3 million increased 3.1% year-over-year as reported and 2.9% in constant currency. Domestic revenue increased 2.8% year-over-year. International revenue increased 3.4% year-over-year as reported and 2.9% in constant currency. Diluted net earnings per share (GAAP) were $0.69, compared to diluted net earnings per share (GAAP) of $0.96 in the second quarter of 2024. Adjusted diluted net earnings per share(1) were $1.15, compared to adjusted diluted net earnings per share of $0.98 in the second quarter of 2024. "We are enco
CONMED Corporation (NYSE:CNMD) today announced that it will report financial results for the second quarter 2025 after the market close on Wednesday, July 30, 2025. The Company's management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via telephone, please click here to pre-register and obtain the dial-in number and passcode. This conference call will also be webcast and can be accessed from the "Investors" section of CONMED's website at www.conmed.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call. About CONMED Corporation CONMED is a medic
CONMED Corporation (NYSE:CNMD) today announced that LaVerne Council has been appointed to succeed Martha Goldberg Aronson as the new Independent Chair of its Board of Directors, effective May 21, 2025. "LaVerne's extensive experience as a global operations and information technology executive have been invaluable to CONMED, and I know that her experience will continue to serve the Board and the Company well in her new role as Chair of the Board," said Pat Beyer, President and Chief Executive Officer, CONMED. "I also want to thank Martha for her ongoing contributions to CONMED. Martha's strategic direction and steady leadership have been crucial to CONMED in her role as Chair, and her conti
CONCORD, Mass.--(BUSINESS WIRE)--Beta Bionics, Inc., a medical technology company focused on the design, development, and commercialization of the iLet® bionic pancreas system, today announced the appointment of Martha Goldberg Aronson as Chair of its Board of Directors, effective immediately. Ms. Aronson, who joined the Beta Bionics Board as a Director in February of 2020, succeeds Ed Damiano, President and Chief Executive Officer of Beta Bionics, who has served as Chair since inception of the company in 2015. Dr. Damiano will remain a member of the Board while continuing to serve in his roles as President and Chief Executive Officer of Beta Bionics. “On behalf of the Board, I am